The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the discoverability, accessibility, and citability of the ALS Research Collaborative (ARC) dataset, a vital resource in the global search for effective ALS treatments.

The collection of a variety of omics data is a key pillar of the ALS Therapy Development Institute’s (ALS TDI) ALS Research Collaborative (ARC) Study, the longest-running natural history study in ALS.

In early May 2025, Timm will embark on a 65-70-day journey that will take him through 10 states, from the shore of the Pacific Ocean in Oregon to the Atlantic Ocean in Virginia.

In anticipation of this year’s walk, we’re interviewing the leaders of some of the event’s biggest and most successful teams.

The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the discoverability, accessibility, and citability of the ALS Research Collaborative (ARC) dataset, a vital resource in the global search for effective ALS treatments.

he ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center (AQTRC), a cutting-edge laboratory dedicated to developing treatments for ALS.